Zobrazeno 1 - 8
of 8
pro vyhledávání: '"D. Kusevich"'
Publikováno v:
Annals of the Rheumatic Diseases. 81:896.1-896
BackgroundOsteoarthritis (OA) associated with metabolic syndrome (MS) or its components is considered as the metabolic phenotype of OA. It is well known that obesity and other components of MS affect the clinical picture, course and progression of OA
Publikováno v:
Annals of the Rheumatic Diseases. 81:896.2-897
BackgroundOne of the common phenotypes of osteoarthritis (OA) is the “inflammatory phenotype,” which is characterized by persistent synovitis of knee joints, small joints of the hands, the development of the erosive hand OA (EOA), and insufficien
Autor:
L. Alekseeva, E. Taskina, N. Kashevarova, D. Kusevich, K. Telyshev, E. Strebkova, E. Sharapova, D. Kudinsky, O. Alekseeva, N. Demin, O. Tenkova, E. Kharlamova, A. Abolyoshina
Publikováno v:
Annals of the Rheumatic Diseases. 81:1613.2-1614
BackgroundThere are more evidence that diabetes mellitus (DM) aggravates the course of osteoarthritis (OA).ObjectivesAt multicenter study to evaluate impact of DM as part of metabolic syndrome on course of knee OA.MethodsThe enrolled patients had kne
Publikováno v:
Annals of the Rheumatic Diseases. 81:1316.1-1316
ObjectivesTo compare the effect of rituximab (RIT) treatment on bone mineral density (BMD) in women with rheumatoid arthritis (RA) and those with RA without biological therapy.Methods78 women over 40 years with confirmed RA according to ACR/EULAR cri
Publikováno v:
Annals of the Rheumatic Diseases. 80:827.1-827
Background:There are many studies about investigation of risk factors (RF) of knee osteoarthritis (OA) radiologic progression. Especially, in patients with small disease duration. At the moment, there are ambivalent of results of previous studies, le
Publikováno v:
Annals of the Rheumatic Diseases. 80:1139.1-1139
Background:Disease modifying anti-rheumatic drugs (DMARD) can provide an unbalanced effect on individual components of the inflammatory process, which in some cases leads to an insufficiently correct assessment of the patient’s status when using co
Publikováno v:
Annals of the Rheumatic Diseases. 80:1337.3-1338
Background:Administration of Chondroitin Sulfate for treatment of osteoarthritis included treatment types include systemic and parenteral therapies. The benefits of local therapies between difference route is ambivalent.Objectives:To evaluate effecti
Publikováno v:
Annals of the Rheumatic Diseases. 80:1131.2-1131
Background:Due to the expiration of many originator biologics patents, their biosimilars (BS) have appeared and were put into clinical practice. The introduction of such drugs reduces the cost of treatment and thereby increases its availability. BS r